Industry 4.0 Technologies for COVID-19 Vaccine Production an | 95999

Первичная медико-санитарная помощь: открытый доступ

ISSN - 2167-1079


Industry 4.0 Technologies for COVID-19 Vaccine Production and Distribution

Divya Sharma

Background: We have conceptualized the application of Industry 4.0 for COVID-19 (coronavirus disease 2019), powered by Industry 4.0 technologies, as a result of the stages of manufacturing evolution. We suggest new intelligent networks along the vaccination value chain using applications of integrated process improvements relying on digital data. Processes for maintenance, logistics, and optimum COVID-19 vaccine production may all be made possible by vaccine 4.0. Vaccine 4.0 Framework: The demand for large-scale technology for digitally transforming vaccine manufacture, production, roll-out, and distribution is one of the challenges in implementing Vaccine 4.0. Vaccine 4.0 analytics will focus on process performance, process development, process stability, compliance, quality assessment, and optimum maintenance using our framework. The ongoing assurance of process control and the effectiveness of big-data analytics in streamlining specified parameter limitations are two advantages of digitalization during and after the COVID-19 epidemic. The effectiveness, efficiency, and manufacturing procedures of largescale vaccine production could all be improved by digitization, including big data analytics. On the road to vaccine 4.0, vaccination quality, effectiveness, and compliance with dataregulated criteria will all be improved. Discussion: Resource-constrained nations all around the world frequently face logistical and financial obstacles. The Vaccine 4.0 architecture takes into account anticipated difficulties in producing and fairly distributing COVID-19 vaccines. By combining big data analytics with biometrics, we make it possible to identify populations that are more susceptible to disease transmission. Robotics and sensors powered by artificial intelligence enable the distribution of thermostable vaccines worldwide in areas with a restricted supply. Biosensors distinguish ineffective COVID-19 vaccines from effective ones. Finally, low- and middle-income nations with constrained distribution capabilities are addressed by vaccine 4.0 blockchain platforms. Conclusion: Vaccine 4.0 is a workable paradigm for enhancing vaccine production before, during, and after the COVID-19 pandemic.